title: Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma.
abstract: The ubiquitin-proteasome pathway is implicated in the pathogenesis of many haematologic malignancies, including multiple myeloma. Under conditions of rapid cell turnover and growth rate, proteasomes are returned into circulation. The measurement of their levels or activity could offer a new approach to diagnosis, prognosis and monitoring of anticancer treatment in carcinoma patients. We analysed proteasome concentration and chymotrypsin-like (ChT-L) activity in the plasma of 64 patients with a newly diagnosed multiple myeloma and 30 healthy volunteers. The values were found to be significantly higher in the studied patients and advanced disease stages compared to the control group, and decreased significant after chemotherapy. Both proteasome concentration and ChT-L activity correlated with adverse prognostic factors, such as lactate dehydrogenase and β2-macroglobulin. We also showed that proteasome concentration positively correlates with IL-6 level, as opposed to proteasome ChT-L activity. Of note, higher proteasome ChT-L activity, unlike the concentration, was proved to be an indicator of a shorter progression free survival, constituting thereby an important prognostic marker.
authors.affiliation: Department of Haematology, Medical University of Bialystok, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Oldziej
authors.affiliation: Department of Haematology, Medical University of Bialystok, Poland. Electronic address: lbolkun@gmail.com.
authors.forename: Lukasz
authors.initials: L
authors.lastname: Bolkun
authors.affiliation: Department of Haematology, Medical University of Bialystok, Poland.
authors.forename: Marzenna
authors.initials: M
authors.lastname: Galar
authors.affiliation: Department of Biology, Medical University of Bialystok, Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Kalita
authors.affiliation: Department of Biology, Medical University of Bialystok, Poland.
authors.forename: Halina
authors.initials: H
authors.lastname: Ostrowska
authors.affiliation: Department of Haematology, Medical University of Bialystok, Poland.
authors.forename: Wioletta
authors.initials: W
authors.lastname: Romaniuk
authors.affiliation: Department of Haematology, Medical University of Bialystok, Poland.
authors.forename: Janusz
authors.initials: J
authors.lastname: Kloczko
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002918:Chymotrypsin / Q000032:analysis / Q000097:blood*; D057075:Enzyme Assays; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis; D046988:Proteasome Endopeptidase Complex / Q000032:analysis / Q000097:blood*; D013792:Thalidomide / Q000008:administration & dosage
chemical_list: D013792:Thalidomide; D002918:Chymotrypsin; D046988:Proteasome Endopeptidase Complex
keywords: Chymotrypsin-like activity; Multiple myeloma; Proteasome